MedTrace Logo

A Cohort Study in Newly Diagnosed MZL

NCT06449885 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2025-11-19

No results posted yet for this study

Summary

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Conditions

Interventions

OTHER

patients receive optimal treatment or follow-up according to the characteristics of the disease

Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Rong Tao, M.D · Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2029-06-30
Completion
2034-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06449885 on ClinicalTrials.gov